The Coalition for Cholera Prevention and Control (CCPC) was established in late 2011 with funding from the Bill & Melinda Gates Foundation to bring together a community of stakeholders to develop a comprehensive strategy for cholera prevention and control. We are a community of 75 organizations and individuals focused on reducing the burden of cholera and ending cholera deaths globally. The Coalition is a Task Force initiative that seeks to bring a comprehensive solution to a perennial disease of poverty. Drawing on the diverse expertise of Coalition members, the group promotes a comprehensive integrated strategy that blends traditional approaches – disease detection, diagnosis, and treatment; safe drinking water, proper disposal of human waste, and hygiene (WaSH) – with appropriate use of recently developed oral cholera vaccines (OCV).
The Coalition and the integrated strategy demonstrate the value of diverse partners working together. In 2013 Coalition work groups developed and released a strategic framework for cholera prevention and control that outlines this approach. The Strategy pulls together existing guidelines addressing the full range of cholera interventions and provides links to the detailed recommendations. Targeted guidance is offered for decision makers as well as program implementers. Download the “Comprehensive Integrated Strategy for Cholera Prevention and Control”.
Cholera is a water-borne illness which plagues people living without clean water and adequate sanitation. Endemic and epidemic cholera are present in many parts of the world and account for approximately 100,000 deaths annually. Widely agreed effective responses to cholera include:
- detection and diagnosis
- treatment with oral or intravenous rehydration fluids and antibiotics
- assuring a safe water supply
- assuring adequate waste disposal and sanitation
ORAL CHOLERA VACCINE
In the last 10-15 years, an important additional intervention has been developed – oral cholera vaccine (OCV). OCV requires two doses of vaccine to be administered approximately two weeks apart. For persons more than one year of age, it confers protection to approximately 70% for a period of at least three years. OCV has been used extensively in demonstrations and field trials in South Asia and Africa and is now recommended for use by the World Health Organization. However, it has not yet been widely adopted for use around the world.